{"filings":[{"id":2502037,"accession_number":"0001193125-26-369426","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-08-27T10:01:18+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.","Board set reverse split at 1-for-7, cutting shares from ~4.7M to ~0.7M; fractional shares paid in cash.","Combined company to trade as Korsana Biosciences, Inc. (KRSA) on Nasdaq from Sept 9, 2026, with new CUSIP 23255M303.","Redomestication failure not a condition to close; merger remains pending with closing conditions to be satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2466318,"accession_number":"0001193125-26-365150","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-08-25T20:15:44+00:00","items":["8.01"],"status":"ready","headline":"Cyclerion sets Sept 4, 2026 record date for CVR distribution in Korsana merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date of Sept 4, 2026 fixed for contingent value rights (CVRs) to holders of common stock and Series A Preferred.","CVRs issued in connection with planned merger with Korsana Biosciences; merger still pending shareholder approval.","CVR payment date, number of CVRs, and terms (transferability, listing) not yet disclosed.","Merger completion remains subject to closing conditions, including obtaining required approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95210,"accession_number":"0001193125-26-137909","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.","$380M PIPE into Korsana led by institutional investors concurrent with merger.","Pre-merger Cyclerion shareholders get CVRs for future proceeds from Akebia license, Tisento stock, and other legacy assets.","Combined co board of 6 all Korsana designees; CEO to be Korsana's president and CEO.","Merger expected to close Q3 2026; subject to Cyclerion shareholder vote, HSR, Nasdaq approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108099,"accession_number":"0001193125-26-053035","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion receives positive FDA feedback for CYC-126 Phase 2 POC study in TRD; remains on track for 2H 2026 initiation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received positive pre-IND written feedback from FDA supporting CYC-126 Phase 2 POC study design in treatment-resistant depression (TRD).","Remains on track to initiate Phase 2 POC study in 2H 2026; first patient in Australia, U.S. enrollment in 1H 2027.","Formed Clinical Advisory Board with five key leaders in neuropsychiatry, anesthesiology, and clinical development.","Selected contract research organization to support multinational study execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108098,"accession_number":"0001193125-26-003509","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion Therapeutics enters collaboration with Medsteer for CYC-126 anesthetic delivery system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cyclerion entered a Collaboration and Option Agreement with Medsteer for an anesthetic delivery system for treatment-resistant depression.","Medsteer granted an exclusive option for a worldwide license of its technology, with upfront nominal payment and up to $3.7M in milestones.","Cyclerion plans to initiate Phase 2 proof-of-concept study of CYC-126 in second half of 2026, targeting first patient in Australia.","Medsteer's technology has been used in over 9,000 patients and 25 clinical settings.","Collaboration includes joint development of closed-loop anesthetic delivery platform with real-time EEG monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124518,"accession_number":"0001193125-25-304067","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclerion to receive $1M milestone if Akebia doses first patient in Phase 2 FSGS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Akebia announced Phase 2 trial initiation for Praliciguat in FSGS; first patient dosing expected in 2026.","Under license amendment, Cyclerion is owed $1.0M upon first patient dosed in a US Phase 2 trial.","The milestone payment is not yet due as dosing has not begun."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141195,"accession_number":"0001193125-25-213332","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.","Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.","Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.","Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158996,"accession_number":"0001193125-25-142765","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclerion shareholders elect all six director nominees at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with >1.3M votes for each; broker non-votes 743,285.","Ratification of Ernst & Young as auditor approved with 2,072,684 for, 57,547 against.","Advisory say-on-pay passed with 1,312,697 for, 78,221 against, 6,203 abstain.","Shareholders selected one-year frequency for future advisory votes on executive compensation.","Proposal to adjourn meeting if needed also approved with 2,036,703 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158995,"accession_number":"0001193125-25-115089","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cyclerion enters $20M ATM equity distribution agreement with Guggenheim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Guggenheim Securities for at-the-market offering of up to $20M of common stock.","Guggenheim will receive 3% commission on gross proceeds; sales limited by public float under Instruction I.B.6.","Company has not sold any securities under Instruction I.B.6 in prior 12 months; current public float below $75M.","Legal opinion from Ropes & Gray covers sale of up to $2,994,080 of Shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177438,"accession_number":"0001193125-25-062612","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cyclerion raises $1.375M in private placement of 499,998 shares at $2.75/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 499,998 shares at $2.75 each to insiders Peter Hecht and Michael Higgins.","Gross proceeds $1.375M; net for general corporate purposes.","Private placement closed March 25, 2025; shares unregistered under Securities Act.","Registration rights agreement requires filing registration statement by May 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194171,"accession_number":"0001193125-24-280125","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.","Tiered royalties increased to mid-single-digit to 20% on net sales; some development milestones reduced.","Exclusive license option for olinciguat granted to entity controlled by CVCO Therapeutics; grantee pays IP costs.","Proceeds will fund CNS pipeline build; company plans to raise capital as needed to support product plans.","Olinciguat option, if exercised, would complete monetization of Cyclerion's historical sGC stimulator portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210491,"accession_number":"0001193125-24-195410","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion promotes Regina Graul, Ph.D., to CEO and President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Regina Graul, Ph.D., promoted to CEO, President, and Board member effective August 7, 2024.","Graul joined Cyclerion as President in December 2023 and led cost reduction and business development efforts.","Company reducing operating costs while evaluating multiple business development prospects for asset in-licensing.","Errol DeSouza, Ph.D., Board Chair, cites Graul's work in assessing new therapies and enhancing shareholder value.","No financial guidance or financial results provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228825,"accession_number":"0001193125-24-161591","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclerion Therapeutics shareholders re-elect all five directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each of five director nominees (De Souza, Hecht, Hyman, Higgins, Katabi) elected with for votes ranging from 1,670,155 to 1,688,966.","Ernst & Young ratified as independent auditor for FY 2024 with 2,140,990 votes for, 47,974 against, 8,751 abstain.","Proposal to adjourn annual meeting if necessary approved with 2,111,217 for, 86,202 against, 296 abstain.","Broker non-votes on director election were 454,351 for each nominee; no other proposals had broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228824,"accession_number":"0001193125-24-100763","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cyclerion sets 2024 annual meeting for June 14, 2024; record date April 17, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting to be held on June 14, 2024 in virtual format.","Record date for shareholder voting is April 17, 2024.","Definitive proxy statement to be filed with SEC by April 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264926,"accession_number":"0001193125-23-288498","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.","Graul earns $372K base salary, bonuses up to $125K, and up to 100K restricted shares vesting over time.","Graul previously VP at EQRx and olinciguat program lead at Cyclerion; 15+ years at Ironwood Pharmaceuticals.","Hecht completed transitional assignment; Cyclerion to rebuild with board additions Dina Katabi and Michael Higgins.","Company to evaluate existing assets and pursue external innovation for next phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264925,"accession_number":"0001193125-23-286790","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cyclerion appoints Michael Higgins and Dina Katabi to Board of Directors; board expands to six members.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.","Higgins appointed Audit Committee Chair; Katabi appointed to Nominating and Corporate Governance Committee.","Higgins is Voyager Therapeutics Chairman and former Ironwood COO; Katabi is MIT professor, MacArthur Fellow, and co-founder of Emerald Innovations.","Compensation: each receives $12,000 cash retainer and 20,000 restricted stock units vesting over 42 months.","Press release signals board refresh to explore possible licenses, mergers, acquisitions, or other investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264924,"accession_number":"0001193125-23-282705","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ole Isacson resigns from Cyclerion board; replacement to be named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ole Isacson, M.D., Ph.D., resigned as director effective November 19, 2023.","He served as Chair of Compensation Committee and member of Audit Committee.","No disagreement with Cyclerion on operations, policies, or practices.","Company expects to appoint a new outside director shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264923,"accession_number":"0001140361-23-049190","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cyclerion CFO Anjeza Gjino to resign; separation includes up to $430K in cash payments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Anjeza Gjino to resign after Q3 2023 10-Q filing; resignation not due to any disagreement.","Receives $226K lump sum on separation, plus $102K each at 6- and 9-month anniversaries if still unemployed.","Vested stock options exercisable for 2 years post-separation; unvested options terminate on effective date.","Non-compete limited to 6 months; agreement includes confidentiality, non-disparagement, and general release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282110,"accession_number":"0001140361-23-035245","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Cyclerion shareholders approve sale of zagociguat/CY3018 assets and CEO stock issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Asset Sale Proposal (95% for) to sell zagociguat (CY6463) and CY3018 programs per May 11 APA.","Shareholders also approved Nasdaq Proposal (96% for) allowing conversion of Series A Preferred held by CEO Peter Hecht into common stock.","Quorum of ~63% (1,515,929 shares) achieved; adjournment proposal not presented due to sufficient votes.","Vote results enable closing of asset sale to JW Celtics Investment Corp. and JW Cycle Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282109,"accession_number":"0000950170-23-032664","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cyclerion discloses lawsuit challenging its asset sale; issues supplemental proxy disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["One lawsuit and five demand letters allege false/misleading proxy statement for the $8M + 10% stock sale to JW Celtics.","Supplemental disclosures: Stifel contacted 65 potential counterparties, 30 signed NDAs; no 'don't-ask-don't-waive' provisions.","Stifel's fee is $1.3M, mostly contingent on closing; $50k retainer credited. DCF shows Purchased Assets value range ($14M)-$4.4M.","CEO Peter Hecht will become CEO of Buyer Parent post-closing and received employment offer; no compensation talks before APA signing.","Non-risk-adjusted revenue projections for zagociguat and CY3018 added; risk-adjusted forecasts also disclosed for 2023-2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301215,"accession_number":"0000950170-23-030168","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"COO Cheryl Gault resigns; effective at close of asset sale to JW Celtics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cheryl Gault resigned as COO effective on closing of the proposed sale of certain assets to JW Celtics Investment Corp.","Separation agreement provides six months of base salary and COBRA subsidies; stock option exercise period extended to 24 months.","Chairman Errol De Souza thanked Gault for her service to operations and the sale transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301214,"accession_number":"0000950170-23-025693","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cyclerion regains compliance with Nasdaq minimum bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received formal notice from Nasdaq of regained compliance with $1.00 minimum bid price rule.","Non-compliance notice received June 1, 2022; compliance achieved after 10 consecutive trading days ending May 30, 2023.","Stock will continue to be listed and traded on the Nasdaq Capital Market; matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301213,"accession_number":"0001140361-23-026621","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"CEO Peter Hecht invests $5M in Cyclerion; receives 225K common shares and 351K Series A convertible preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peter Hecht, CEO, purchased $5M in equity at $8.68 per share (post-1-for-20 reverse split).","Issued 225,000 shares of common stock and 351,037 shares of Series A convertible preferred (1:1 conversion).","Hecht agreed not to convert preferred if it would require Nasdaq shareholder approval.","Transaction completed May 19, 2023; exempt from registration under Regulation D and Section 4(a)(2).","Filed Articles of Amendment to designate Series A Preferred Stock; no shareholder approval needed for issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301212,"accession_number":"0001140361-23-024768","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","8.01","9.01"],"status":"ready","headline":"Cyclerion announces 1-for-20 reverse stock split effective May 15, reduces shares to ~2.18M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-20 reverse split effective 5:00 PM ET May 15; trading begins split-adjusted May 16 under symbol CYCN.","Post-split outstanding shares approximately 2,176,244; fractional shares paid at $0.2232 per share.","Stockholders approved reverse split at annual meeting: 29,493,422 for, 2,912,129 against, 45,310 abstain.","All outstanding options, warrants, and RSUs proportionately adjusted; no change in authorized shares or par value.","Directors elected and Ernst & Young ratified as independent auditor for fiscal year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301211,"accession_number":"0001140361-23-024218","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","2.02","7.01","3.02","8.01","9.01"],"status":"ready","headline":"Cyclerion sells zagociguat & CY3018 for $8M cash + 10% equity; CEO to lead NewCo","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Receives $8M cash at closing and 10% equity in NewCo with anti-dilution protection through $100M post-money.","NewCo investors (Invus, Venrock, J Wood Capital, Sanofi Ventures) commit $81M to develop zagociguat and CY3018.","CEO Peter Hecht will transition to NewCo as CEO; Errol De Souza elected Chair of Cyclerion Board.","Signing triggers $5M equity investment by Hecht at $0.434/share; proceeds plus $8M expected to fund operations for 12+ mos.","Q1 2023 cash $7.2M (down from $13.4M year-end 2022); company to seek later-stage CNS assets under new leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301210,"accession_number":"0000950170-23-011500","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion enters exclusive talks to sell zagociguat/CY3018; CEO to invest $5M","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Non-binding proposal from entity including CEO Peter Hecht to buy zagociguat and CY3018 assets.","Independent Board concluded proposal merits pursuit; exclusive negotiation period underway.","Binding agreement for CEO to invest $5M in cash for stock or convertible preferred stock.","CEO equity investment closes 6 business days after definitive asset sale documents signed.","Proceeds intended to support ongoing operations; deal subject to board and shareholder approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321077,"accession_number":"0000950170-23-009221","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.","Net loss $44.1M for FY 2022 vs $51.6M in FY 2021; R&D spend $31.5M, G&A $14.5M.","Met with FDA in Q4 2022; filed for Orphan Drug Designation for zagociguat in MELAS.","Refined Phase 2b design for zagociguat; manufactured drug product to support the study.","Company actively evaluating capital, capabilities, or transactions to advance pipeline and maximize value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339183,"accession_number":"0000950170-22-025791","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cyclerion gets 180-day bid price extension; transfers to Nasdaq Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension to May 29, 2023 to regain $1.00 minimum bid price compliance.","Company transferred from Nasdaq Global Market to Capital Market on Nov 25, 2022.","Bid price below $1.00 for 30 consecutive business days; needs 10 consecutive days at $1.00+.","If not cured by May 29, 2023, common stock will be delisted (subject to appeal).","Company intends to cure deficiency via reverse stock split, if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339182,"accession_number":"0000950170-22-025613","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cyclerion board rejects unsolicited CEO-led asset purchase proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unsolicited proposal received Nov 20, 2022 from group including CEO to purchase certain assets.","Independent board unanimously concluded proposal is not in the best interest of the Company.","Board consulted legal and financial advisors prior to reaching its decision.","Company will not make further statements on M&A activity unless deemed appropriate or necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339181,"accession_number":"0000950170-22-019330","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Cyclerion cuts 45% of workforce, focuses on mitochondrial disease after positive MELAS data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by ~45% (13 employees) in Q4 2022 to align with mitochondrial disease strategy.","Estimated severance charge of ~$1.9M in Q4 2022; expects annual cash savings of ~$4.1M.","Plans to meet with FDA in Q4 2022 to discuss CY6463 development path for MELAS.","ADv study enrollment capped; data expected H1 2023; CIAS program CY3018 to seek partnership.","Will out-license olinciguat and praliciguat; praliciguat already licensed to Akebia for milestones/royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356553,"accession_number":"0000950170-22-019124","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CSO Andreas Busch resigns effective Sept 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andreas Busch, Ph.D. resigned as Chief Scientific Officer, effective Sept 30, 2022.","Dr. Busch left to pursue another opportunity; no disagreement with Company's operations, policies or practices.","No successor has been named; search process not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356552,"accession_number":"0000950170-22-016016","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.","CY6463 showed improvements in biomarkers, cognitive performance, safety in MELAS and CIAS studies.","Appointed Steven E. Hyman, M.D. to Board of Directors effective July 25, 2022.","Enrollment ongoing in Phase 2a Alzheimer's disease with vascular pathology study; topline results expected 2023.","R&D expenses $10.2M, G&A $3.5M; both down YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1017000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356551,"accession_number":"0000950170-22-013289","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.","No SAEs, severe AEs, or discontinuations due to AEs; all adverse events transient.","Favorable changes observed in broad panel of plasma inflammatory biomarkers linked to schizophrenia.","48 adults with stable schizophrenia on single atypical antipsychotic; PK linear dose-proportional.","Company exploring partnerships; webinar July 28 at 8:00 a.m. EDT to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356550,"accession_number":"0001140361-22-026908","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cyclerion appoints Steven E. Hyman to board; former NIMH director and neuroscience leader","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Hyman appointed to Board effective July 25, 2022, following Board expansion from 8 to 9 members.","Hyman serves on Science Committee; is director of Stanley Center for Psychiatric Research at Broad Institute.","Previously served as director of NIMH (1996-2001) and provost of Harvard University (2001-2011).","Will help shape clinical strategy for lead molecule CY6463 and expand external collaborations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374991,"accession_number":"0000950170-22-011675","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cyclerion Therapeutics stockholders elect directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected eight directors: Conrades, De Souza, Fanucci, Hecht, Isacson, Lovell, McGuire, Mendelsohn; each received over 22.4 million votes for.","Ratified Ernst & Young as independent auditor for fiscal 2022 with 30,226,143 votes for, 53,476 against, 13,639 abstain.","Broker non-votes totaled 7,253,724 on all director elections.","Annual meeting held June 14, 2022; all proposals passed as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374990,"accession_number":"0000950170-22-011430","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion (CYCN) reports positive topline data for CY6463 in MELAS study; improvements in biomarkers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Open-label, eight-patient study showed improvements in lactate, GDF-15, inflammatory biomarkers, cerebral blood flow, and functional connectivity after 29 days.","CY6463 was well tolerated with no serious adverse events or treatment discontinuations; PK consistent with Phase 1.","75% of patients were on standard-of-care arginine or citrulline; effects more pronounced in patients with greater baseline disease burden.","Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction, including schizophrenia and Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374989,"accession_number":"0000950170-22-011148","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cyclerion receives Nasdaq deficiency notice for bid price below $1; 180-day cure period to Nov 28, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on June 1, 2022, for failing minimum $1 bid price for 30 consecutive business days.","Has until November 28, 2022, to regain compliance with bid price closing at $1 for 10 consecutive days.","May transfer to Nasdaq Capital Market or effect a reverse stock split if needed to cure the deficiency.","No assurance of regaining compliance; failure could lead to delisting and appeal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374988,"accession_number":"0000950170-22-007369","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).","R&D expenses rose to $9.7M from $8.0M due to external research costs; G&A fell to $4.0M from $5.4M.","MELAS study enrollment closed; topline data expected Q2 2022.","CIAS study enrollment closed; topline data expected Q3 2022.","Alzheimer's disease with vascular pathology (ADv) study enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":711000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393395,"accession_number":"0000950170-22-001956","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.","R&D expense $37.6M (down from $56.4M); G&A $20.6M (down from $28.8M).","Phase 2a MELAS trial enrollment closed; topline data expected in Q2 2022.","Phase 1b CIAS trial enrollment ongoing; topline expected H2 2022; Phase 2a ADv trial initiated.","Bruce Kinon appointed VP Clinical Development; collaboration with Ariana Pharma for AI biomarker discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":3942000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411916,"accession_number":"0000950170-21-003725","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.","Cash, cash equivalents, and restricted cash $63M, down from $70M at June 30, 2021.","First patients enrolled in CIAS study (CY6463); patient screening underway in ADv study.","MELAS study enrollment slowed by COVID-19; topline clinical results expected H1 2022.","G&A expenses decreased to $4.6M from $8.0M, driven by lower salaries and financing fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":3409000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411915,"accession_number":"0001140361-21-035774","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cyclerion appoints CEO Peter Hecht as interim CFO during CFO's maternity leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter M. Hecht, CEO, appointed Interim CFO effective October 27, 2021 while Anjeza Gjino is on maternity leave.","Upon Ms. Gjino's return, she will resume her CFO role and Dr. Hecht will return to CEO duties.","Other officers have assumed some of Ms. Gjino's responsibilities during her absence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430645,"accession_number":"0001140361-21-033010","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2021-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).","Phase 2a in MELAS remains enrolling; topline clinical results now expected in H1 2022.","Patient screening started in Phase 2a study of CY6463 for Alzheimer's disease with vascular pathology (ADv)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430644,"accession_number":"0001140361-21-028904","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2021-08-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kevin B. Churchwell resigns from Cyclerion board effective Aug 18, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin B. Churchwell, M.D. resigned from the board of directors on August 18, 2021.","No disagreement with company operations, policies, or practices cited.","Resignation due to expanded responsibilities as CEO of Boston Children's Hospital.","Marsha Fanucci, Board Chair, thanked Churchwell for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430643,"accession_number":"0001564590-21-039201","cik":1755237,"company_name":"Cyclerion Therapeutics, Inc.","ticker":"CYCN","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cyclerion Q2 net loss $16.2M; cash $70M; pipeline advances; praliciguat licensed to Akebia for up to $585M milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.","CY6463 Phase 2a trial initiated in Alzheimer's with vascular pathology (ADv); Ph1b in CIAS start-up; MELAS data expected by year-end 2021.","Exclusive global license of praliciguat to Akebia Therapeutics; Cyclerion eligible for up to $585M milestones plus tiered royalties.","Closed $18M private placement with EcoR1, Slate Path, MFN, Invus, and others; net $12.5M from ATM offering in Q2.","Errol De Souza appointed to Board of Directors; expanded Beacon Biosignals partnership for biomarker identification."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3062000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13857005.714285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}